STOCK TITAN

MacroGenics Announces Leadership Transition

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

MacroGenics (NASDAQ: MGNX) announced that CEO Scott Koenig will step down in early 2025. The Board has engaged Heidrick & Struggles to search for a new CEO and formed a special committee to oversee the transition. Under Koenig's 24-year leadership, MacroGenics developed three FDA-approved therapeutics: MARGENZA®, ZYNYZ® for cancer treatment, and TZIELD® for Type 1 diabetes. The company secured over $1 billion in non-dilutive capital through partnerships since its 2013 IPO and maintains a strong balance sheet with multiple antibody-based therapeutics in development.

MacroGenics (NASDAQ: MGNX) ha annunciato che il CEO Scott Koenig si dimetterà all'inizio del 2025. Il Consiglio ha incaricato Heidrick & Struggles di cercare un nuovo CEO e ha costituito un comitato speciale per supervisionare la transizione. Sotto la leadership di Koenig, durato 24 anni, MacroGenics ha sviluppato tre terapie approvate dalla FDA: MARGENZA®, ZYNYZ® per il trattamento del cancro e TZIELD® per il diabete di tipo 1. L'azienda ha ottenuto oltre 1 miliardo di dollari in capitale non diluitivo attraverso partnership dalla sua IPO nel 2013 e mantiene un solido bilancio con diversi terapeutici basati su anticorpi in fase di sviluppo.

MacroGenics (NASDAQ: MGNX) anunció que el CEO Scott Koenig renunciará a principios de 2025. La Junta ha contratado a Heidrick & Struggles para buscar un nuevo CEO y ha formado un comité especial para supervisar la transición. Durante los 24 años de liderazgo de Koenig, MacroGenics desarrolló tres terapias aprobadas por la FDA: MARGENZA®, ZYNYZ® para el tratamiento del cáncer y TZIELD® para la diabetes tipo 1. La compañía ha asegurado más de 1 mil millones de dólares en capital no dilutivo a través de asociaciones desde su salida a bolsa en 2013 y mantiene un balance sólido con múltiples terapias basadas en anticuerpos en desarrollo.

MacroGenics (NASDAQ: MGNX)는 CEO 스콧 코닌이 2025년 초에 사임할 것이라고 발표했습니다. 이사회는 새로운 CEO를 찾기 위해 헤이드릭 & 스트러글스를 고용하고 전환을 감독할 특별 위원회를 구성했습니다. 코닌의 24년간의 리더십 아래 MacroGenics는 FDA 승인을 받은 세 가지 치료제를 개발했습니다: MARGENZA®, ZYNYZ® 암 치료제와 TZIELD® 1형 당뇨병 치료제. 이 회사는 2013년 IPO 이후 파트너십을 통해 10억 달러 이상의 비 희석 자본을 확보했으며, 여러 항체 기반 치료제가 개발 중인 강력한 재무 상태를 유지하고 있습니다.

MacroGenics (NASDAQ: MGNX) a annoncé que le PDG Scott Koenig démissionnera début 2025. Le Conseil a engagé Heidrick & Struggles pour rechercher un nouveau PDG et a formé un comité spécial pour superviser la transition. Sous la direction de Koenig pendant 24 ans, MacroGenics a développé trois thérapeutiques approuvées par la FDA : MARGENZA®, ZYNYZ® pour le traitement du cancer et TZIELD® pour le diabète de type 1. L'entreprise a sécurisé plus de 1 milliard de dollars en capital non dilutif grâce à des partenariats depuis son introduction en bourse en 2013 et maintient une solide situation financière avec plusieurs thérapeutiques basées sur des anticorps en développement.

MacroGenics (NASDAQ: MGNX) gab bekannt, dass CEO Scott Koenig Anfang 2025 zurücktreten wird. Der Vorstand hat Heidrick & Struggles beauftragt, nach einem neuen CEO zu suchen, und einen Sonderausschuss gebildet, um den Übergang zu überwachen. Unter Koenigs 24-jähriger Leitung entwickelte MacroGenics drei von der FDA zugelassene Therapeutika: MARGENZA®, ZYNYZ® zur Krebsbehandlung und TZIELD® zur Behandlung von Typ-1-Diabetes. Das Unternehmen sicherte sich seit dem IPO im Jahr 2013 über 1 Milliarde Dollar an nicht verwässerndem Kapital durch Partnerschaften und hält eine starke Bilanz mit mehreren in Entwicklung befindlichen, auf Antikörpern basierenden Therapeutika.

Positive
  • Successfully developed and commercialized three FDA-approved therapeutics
  • Secured over $1 billion in non-dilutive capital through partnerships since IPO
  • Strong balance sheet maintained
  • Broad portfolio of assets in development
Negative
  • Potential leadership uncertainty during CEO transition period
  • Scott Koenig, M.D., Ph.D., to step down as President and CEO
  • Board to initiate search process to identify new CEO

ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.

William Heiden, Chairman of the Board of Directors said, “Scott was a co-founder of MacroGenics twenty-four years ago and the Company has achieved many milestones under his leadership – including several partnered or company-owned FDA approved monoclonal antibody therapeutics developed by the company.  On behalf of the Board, I want to thank Scott for his incredible dedication to the Company’s mission of discovering and developing novel therapeutics to improve patient care.”

Mr. Heiden continued, “Today, MacroGenics has several innovative antibody-based therapeutics in development for the treatment of cancer, as well as significant alliances with leading pharmaceutical and biotechnology companies to develop and commercialize novel therapeutics.  The Company today has a broad portfolio of promising assets and a strong balance sheet, and the Board and Scott agreed that this is the right time to transition to our next phase of leadership. We look forward to continuing to benefit from his perspectives as an advisor and shareholder.”

“I am proud of our many achievements since our founding in 2000, in which we built a fully integrated, science-focused biotechnology company and have been successful in discovering, developing, manufacturing, and commercializing novel immunotherapeutics derived from our proprietary Fc-engineered antibody, bi-specific DART molecule, and antibody drug conjugate (ADC) technologies,” said Dr. Koenig. “Since the company’s IPO in 2013, we were able to fund a significant part of the development portfolio through the achievement of over $1 billion of non-dilutive capital via partnerships. Thanks to the incredible passion and dedication of the people at MacroGenics, three novel therapeutics from our pipeline advanced to approval, including MARGENZA® and ZYNYZ® to treat patients with cancer, and TZIELD® for individuals with early-stage Type 1 diabetes, and we have advanced a rich portfolio of clinical and preclinical molecules in development.  I am confident that MacroGenics is well positioned in its current mission to address the significant unmet medical needs of patients with cancer.   I look forward to continuing to support the Company in its work to achieve its key strategic objectives and create value for all our stakeholders.”

About MacroGenics, Inc.

MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. 

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of final safety and efficacy data, including mature median rPFS and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, especially timing and results of mature median radiographic progression-free survival, other efficacy and safety data with respect to vobramitamab duocarmazine; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

###


FAQ

When will Scott Koenig step down as MacroGenics (MGNX) CEO?

Scott Koenig will step down as President and CEO of MacroGenics early next year (2025).

How many FDA-approved therapeutics has MacroGenics (MGNX) developed under Koenig's leadership?

Under Koenig's leadership, MacroGenics developed three FDA-approved therapeutics: MARGENZA and ZYNYZ for cancer treatment, and TZIELD for Type 1 diabetes.

How much non-dilutive capital has MacroGenics (MGNX) raised through partnerships since its IPO?

MacroGenics has raised over $1 billion in non-dilutive capital through partnerships since its IPO in 2013.

Who is conducting the CEO search for MacroGenics (MGNX)?

Heidrick & Struggles has been retained to lead the search process for MacroGenics' next CEO.

MacroGenics, Inc.

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Stock Data

204.36M
58.33M
2.64%
93.46%
8.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
Rockville